Evidence map›Paper›PMID 37860277›Full record

ArticleOncoimmunology2023

A mitochondrial checkpoint to adaptive anticancer immunity.

Oliver Kepp, Peng Liu, Guido Kroemer, Lorenzo Galluzzi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 3 countries.

Oliver KeppCentre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.ORCID 0000-0002-6081-9558
Peng LiuCentre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.
Guido KroemerCentre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.ORCID 0000-0002-9334-4405
Lorenzo GalluzziDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0003-2257-8500
Inserm · FRCornell University · US

Funding

Radiation Effect on Immune Cells and the MicrobiomeU54CA274291 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Encouse Golden · 2022 to 2026
$9.1M
Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancerR01CA271915 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Lorenzo Galluzzi · 2023 to 2026
$2.9M
NCI NIH HHS R01 CA271915NCI NIH HHS U54 CA274291
6 · The paper itself

Abstract

BCL2 robustly preserves mitochondrial integrity, hence inhibiting innate immune signaling and apoptotic cell death in several cell types. Here, we comment on our recent data demonstrating that BCL2 also limits the ability of dendritic cells to elicit adaptive immune responses, lending support to a universal immunosuppressive function for the mitochondrial immune checkpoint.

Indexed as

Proto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-2Antigen presentationCGASimmune checkpoint inhibitorsimmunogenic cell deathmtDNAtype I interferon

Identifiers

PMID37860277
PMCPMC10583618
OpenAlexW4387694795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.